- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00210340
A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis
March 27, 2015 updated by: International Extranodal Lymphoma Study Group (IELSG)
The purpose of this study is to define the safety profile of rituximab given intrathecally in lymphomatous meningitis related to CD20+ non-Hodgkin's lymphomas.
Study Overview
Study Type
Interventional
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Lymphomatous meningitis documented by positive CSF cytology in either newly diagnosed, relapsed or refractory primary CNS or systemic NHL
- Pathologically diagnosed CD20-positive NHL
- Age ≥ 18 years
- ECOG Performance Status 0 - 2 (See Appendix A)
- Life expectancy of at least 1 month
- Informed consent must be given according to national/local regulations before enrollment (See Appendix B)
- Patients may have had prior CNS irradiation, intrathecal methotrexate, cytarabine or thiotepa for treatment of lymphomatous meningitis but these treatments must have completed at least two weeks before the study enrollment and the patients must have recovered from any reversible toxicity caused by prior treatments
- Concurrent systemic chemotherapy is allowed with the exception of high-dose methotrexate (>500 mg/m2/day), high-dose cytarabine (>2 g/m2/day), high-dose thiotepa (>300 mg/m2/day) or investigational agents
- No concurrent intrathecal chemotherapy other than rituximab
- No severe impairment of bone marrow function (ANC >1.5x109/L, PLT >50x109/L), unless due to proven lymphoma involvement
- No major impairment of renal function (serum creatinine < 1,5 x upper normal) or liver function (ASAT/ALAT < 2,5 upper normal, total bilirubin <2,5x upper normal), unless due to proven lymphoma involvement
- No evidence of active opportunistic infections
- No HIV infection
- No pregnant or lactating status
- Appropriate contraceptive method in women of childbearing potential or men
- Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
- Absence of a obstructive hydrocephalus or compartimentalization of CSF flow.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Safety profile of rituximab given intrathecally
|
Secondary Outcome Measures
Outcome Measure |
---|
preliminary evaluation of the antitumor activity of i.t. rituximab
|
collection of CSF samples devoted to ancillary biological studies
|
pharmacokinetics of different dose levels of intrathecal rituximab
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Annarita Conconi, MD, International Extranodal Lymphoma Study Group/Hematology Division. University Amedeo Avogadro. Novara
- Study Chair: Andres JM Ferreri, MD, Radiochemotherapy San Raffaele Hospital. Milan
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
September 13, 2005
First Submitted That Met QC Criteria
September 13, 2005
First Posted (Estimate)
September 21, 2005
Study Record Updates
Last Update Posted (Estimate)
March 30, 2015
Last Update Submitted That Met QC Criteria
March 27, 2015
Last Verified
March 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Neoplasms by Site
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Lymphoma
- Meningeal Neoplasms
- Lymphoma, B-Cell
- Meningitis
- Meningeal Carcinomatosis
- Physiological Effects of Drugs
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Rituximab
Other Study ID Numbers
- IELSG24
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma, B Cell
-
Nathan DenlingerBristol-Myers SquibbRecruitingB-Cell Non-Hodgkin Lymphoma-Recurrent | Diffuse Large B-Cell Lymphoma-Recurrent | Follicular Lymphoma-Recurrent | High Grade B-Cell Lymphoma-Recurrent | Primary Mediastinal Large B-Cell Lymphoma-Recurrent | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent and other conditionsUnited States
-
Iksuda Therapeutics Ltd.RecruitingFollicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Non-Hodgkin LymphomaAustralia, Canada, United States
-
AstraZenecaRecruitingFollicular Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | B-cell Non Hodgkin LymphomaKorea, Republic of, United States, Japan, Australia, Taiwan
-
Memorial Sloan Kettering Cancer CenterRecruitingLymphoma | Lymphoma, B-Cell | DLBCL - Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma | Large-cell Lymphoma | Mediastinal B-Cell Diffuse Large Cell LymphomaUnited States
-
University of ChicagoMerck Sharp & Dohme LLCRecruitingLymphoma | Lymphoma, B-Cell | B Cell Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell LymphomaUnited States
-
Curocell Inc.RecruitingHigh-grade B-cell Lymphoma | Diffuse Large B-cell Lymphoma (DLBCL) | Primary Mediastinal Large B-Cell Lymphoma (PMBCL) | Transformed Follicular Lymphoma (TFL) | Refractory Large B-cell Lymphoma | Relapsed Large B-cell LymphomaKorea, Republic of
-
Massachusetts General HospitalVarian Medical SystemsRecruitingLymphoma, B-Cell | Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Lymphoma | High-grade B-cell Lymphoma | Relapsed Cancer | Mediastinal Large B-cell LymphomaUnited States
-
Qian WenbinNot yet recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaChina
-
University of NebraskaBristol-Myers SquibbRecruitingFollicular Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | DLBCL - Diffuse Large B Cell Lymphoma | Relapsed Non-Hodgkin Lymphoma | Mediastinal Large B-cell Lymphoma | Indolent B-Cell Non-Hodgkin LymphomaUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)Active, not recruitingDiffuse Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma, Not Otherwise Specified | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | Diffuse Large B-Cell Lymphoma... and other conditionsUnited States
Clinical Trials on intrathecal rituximab
-
M.D. Anderson Cancer CenterTerminatedLeukemia | Metastatic Malignant Neoplasm to the Leptomeninges | Lymphoid MalignanciesUnited States
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityCompletedLymphoma, Non-Hodgkin | Child, Only
-
Tisch Multiple Sclerosis Research Center of New...CompletedMultiple SclerosisUnited States
-
Moens MaartenCompleted
-
International Stemcell Services LimitedCompletedSpinal Cord InjuriesIndia
-
Royan InstituteCompletedAmyotrophic Lateral SclerosisIran, Islamic Republic of
-
Centre Hospitalier Universitaire de NiceActive, not recruitingSpinal Muscular AtrophyFrance
-
Dr med. Paolo Maino Viceprimario AnestesiologiaVU University of AmsterdamCompleted
-
Tisch Multiple Sclerosis Research Center of New...No longer available
-
Hospital Universitario Dr. Jose E. GonzalezCompletedAmyotrophic Lateral SclerosisMexico